---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-061631"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:28:55.853743+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TriSalus Q1 revenue up 116% to $6.5M, secures $50M OrbiMed debt facility

## Summary
- Revenue of $6.5M in Q1 2024, up 116% YoY; gross margin improved to 85% from 78%.
- Net loss available to common stockholders was $13.2M ($0.60 per share) vs $8.3M loss in Q1 2023.
- Closed $25M initial draw on up to $50M debt financing with OrbiMed; expects runway through end of 2024.
- Appointed Liselotte Hyveled, Chief Patient Officer at Novo Nordisk, to Board of Directors.
- Management reiterates full-year revenue growth guidance exceeding 50%.

## SEC filing metadata
- accession: 0001104659-24-061631
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000110465924061631/0001104659-24-061631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000110465924061631/tm2414537d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-061631
- JSON: https://secwatch.observer/filing/0001104659-24-061631.json
- Plain text: https://secwatch.observer/filing/0001104659-24-061631.txt

## Key facts
- Earnings Releases
  TriSalus Life Sciences, Inc. reported first quarter ended March 31, 2024 results: revenue $6.5 million, net income $13.2 million, EPS $0.60.
  - Period: first quarter ended March 31, 2024
  - Revenue: $6.5 million
  - Net income: $13.2 million
  - EPS: $0.60
  - Result: reported results
  source text: TriSalus Reports Q1 2024 Financial Results and Business Update · Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 · Reported Gross Margin of 85% in 1Q24
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465924061631/0001104659-24-061631-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.